{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PART+1%3A+Double-blind+Placebo-controlled&page=2",
    "query": {
      "intervention": "PART 1: Double-blind Placebo-controlled",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 714,
    "total_pages": 72,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PART+1%3A+Double-blind+Placebo-controlled&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PART+1%3A+Double-blind+Placebo-controlled&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T18:07:12.004Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04172441",
      "title": "Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Congenital Hyperinsulinism"
      ],
      "interventions": [
        {
          "name": "dasiglucagon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zealand Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "364 Days",
        "sex": "ALL",
        "summary": "7 Days to 364 Days"
      },
      "enrollment_count": 12,
      "start_date": "2020-06-19",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Fort Worth, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172441"
    },
    {
      "nct_id": "NCT04783545",
      "title": "Phase I Study of VLX-1005 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety and Tolerability in Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "VLX-1005",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veralox Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2021-03-24",
      "completion_date": "2022-01-11",
      "has_results": false,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04783545"
    },
    {
      "nct_id": "NCT05462106",
      "title": "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyloid Plaque",
        "Beta-Amyloid",
        "DSAD",
        "Prodromal Alzheimer's Disease",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo (Study Part 1a)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose A in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose B in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose C in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Study Part 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose A in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose B in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose C in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Study Part 1b)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AC Immune SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "35 Years to 85 Years"
      },
      "enrollment_count": 304,
      "start_date": "2022-06-21",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lady Lake",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05462106"
    },
    {
      "nct_id": "NCT02600715",
      "title": "Reduction of Bladder Injection Pain With Belladonna Opiate Suppository",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder",
        "Urinary Urge Incontinence",
        "Urinary Bladder, Neurogenic",
        "Painful Bladder Syndrome"
      ],
      "interventions": [
        {
          "name": "Onabotulinumtoxin A (BoNT)",
          "type": "DRUG"
        },
        {
          "name": "belladonna",
          "type": "DRUG"
        },
        {
          "name": "Morphine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Active B&O suppository of belladonna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edgar LeClaire, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2015-11",
      "completion_date": "2017-06-26",
      "has_results": true,
      "last_update_posted_date": "2018-09-20",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 2,
      "location_summary": "Wichita, Kansas",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02600715"
    },
    {
      "nct_id": "NCT07601425",
      "title": "Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia (HHT)",
        "Osler Weber Rendu Disease"
      ],
      "interventions": [
        {
          "name": "ATV-1601",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atavistik Bio, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-07-27",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Augusta, Georgia • Indianapolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07601425"
    },
    {
      "nct_id": "NCT06279234",
      "title": "A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "PF-06954522",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-02-20",
      "completion_date": "2025-04-11",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • South Miami, Florida",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06279234"
    },
    {
      "nct_id": "NCT05047185",
      "title": "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "Hereditary Angioedema Type I",
        "Hereditary Angioedema Type II",
        "Hereditary Angioedema Types I and II",
        "Hereditary Angioedema Attack",
        "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency",
        "Hereditary Angioedema - Type 1",
        "Hereditary Angioedema - Type 2",
        "C1 Esterase Inhibitor Deficiency",
        "C1 Inhibitor Deficiency"
      ],
      "interventions": [
        {
          "name": "Deucrictibant low dose",
          "type": "DRUG"
        },
        {
          "name": "Deucrictibant high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharvaris Netherlands B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 34,
      "start_date": "2022-04-19",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05047185"
    },
    {
      "nct_id": "NCT04565717",
      "title": "A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis",
        "NASH"
      ],
      "interventions": [
        {
          "name": "ALN-HSD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2020-10-09",
      "completion_date": "2023-12-21",
      "has_results": false,
      "last_update_posted_date": "2024-05-17",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 7,
      "location_summary": "Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Fleming Island",
          "state": "Florida"
        },
        {
          "city": "Marrero",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Hermitage",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04565717"
    },
    {
      "nct_id": "NCT06610279",
      "title": "A Study of TAK-951 in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-951",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2022-01-07",
      "completion_date": "2023-09-21",
      "has_results": true,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06610279"
    },
    {
      "nct_id": "NCT05540860",
      "title": "A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Sevasemten Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Sevasemten Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Sevasemten Dose 3",
          "type": "DRUG"
        },
        {
          "name": "Sevasemten Dose 4",
          "type": "DRUG"
        },
        {
          "name": "Sevasemten Dose 5",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edgewise Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "9 Years",
        "sex": "MALE",
        "summary": "4 Years to 9 Years · Male only"
      },
      "enrollment_count": 76,
      "start_date": "2022-10-24",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-10T18:07:12.004Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05540860"
    }
  ]
}